An observational study in Brain (Nervous System) Cancers, Brain Arterial Disease and Neuro-Degenerative Disease, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-08-17.
Sponsored by Xiangya Hospital of Central South University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Neurologic Manifestations with a site in China — 11 open to participants now, 11 under way, none of them phase 3. Neurologic Manifestations · China.
Among the 24 studies in Neurologic Manifestations with a site in China, this one has the largest planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2025, is one of 10 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 21st registered.
427 studies on the registry are indexed under Neurologic Manifestations; 80 are open to participants now.
Browse Neurologic Manifestations studies →11 of the 24 studies in Neurologic Manifestations with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Zhejiang Chinese Medical University · Sites in China
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 14–65
First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University · Sites in China
Ages 20–80
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 30–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 59 Neurologic Manifestations studies recruiting now, 31 (53%) set no upper age limit and 15 (25%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100,000 is above the median of 141 across 131 observational studies indexed under Neurologic Manifestations.
Median enrollment 69 across the 14 interventional studies, 231 across the 10 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 24 have an industry lead sponsor. The 10 most frequent:
Xiangya Hospital of Central South University is the lead sponsor of 177 studies on the registry; 80 are open to participants now.
Xiangya Hospital of Central South University has 1 study filed under Neurologic Manifestations — fewer than ten, so there is no comparison to draw.
1 of the studies in Neurologic Manifestations with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03979235National Research Center for Rehabilitation Technical AidsDeveloping Effectiveness Evaluation and Therapeutic Programs of Rehabilitation | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Neurologic Manifestations with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to develop an innovative, comprehensive, and explainable AI vision-language foundation model (VLM) to advance the diagnosis and interpretation of brain diseases using multi-modal data. We will include patient demographics, medical imaging data (such as MRI, CT, and PET scans), histopathological data, genomic data when available, and other necessary laboratory examinations and tests to establish a screening and diagnostic model for brain diseases.
Secondary Objective: To establish a comprehensive diagnostic model with uncertainty quantification and automated report generation that covers all brain diseases based on clinical indicators.
Exploratory Objective: To include MRI scans from large-scale populations for model validation.
Patients with brain disease or Non-disease condition
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with brain diseases:
Non-brain disease population:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No Interventions
Brain Disease Diagnostic performance
This study will evaluate how accurately the AI model can identify and differentiate between: 1. Brain tumors including gliomas, glioneuronal tumors, and neuronal tumor, meningioma, germ cell tumors, embryonal tumors, tumors of the sellar region, pineal region tumors, mesenchymal, non-meningothelial tumors, choroid plexus tumors, hematolymphoid tumors, cranial and paraspinal nerve tumors, melanocytic tumors and brain metastases based on WHO CNS 5 classification; 2. Brain diseases apart from brain tumors such as brain arterial disease, neurodegenerative disorders, etc.; 3. Normal brain findings; The model's performance will be assessed using sensitivity, specificity, F1-score AUC-ROC. Diagnostic ability of AI model will be compared against with pathological diagnosis(if possible), final clinical diagnoses by neurologists or radiologists.
Time frame: Perioperative
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2030, 67 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiangya Hospital of Central South University →